TARSUS PHARMACEUTICALS INC

Company Overview

Tarsus Pharmaceuticals Inc. (Healthcare / Biotechnology) is a commercial-stage ophthalmology company that is rapidly scaling the launch of XDEMVY, which generated $102.7M of net product sales in Q2 2025 (up 152% YoY) and ~91,000 bottles dispensed. Management attributes growth to expanded payer coverage (>90% of covered lives), a material DTC advertising program, and broader ECP adoption (20,000+ active prescribers). The company is investing heavily in commercial infrastructure (large SG&A increase) while advancing clinical programs (TP‑04, TP‑05) and pursuing international regulatory paths (Japan interactions H2 2025; potential EU approval 2027). Cash, cash equivalents and marketable securities totaled $381.1M at 6/30/2025 and management expects at least a 12‑month runway though additional capital may be needed depending on commercialization and clinical timelines.

Executive Compensation Practices

Compensation at Tarsus is likely to emphasize commercialization and revenue-growth metrics given XDEMVY’s rapid launch—net product sales, net revenue after gross‑to‑net discounts (~45%), new prescriber adoption, and payer coverage expansion are the most direct drivers for short‑term incentives. Long‑term pay will typically link to clinical and regulatory milestones (progression of TP‑04/TP‑05, EU/Japan approvals), equity performance and retention as the company balances continued investment with potential future dilution. Expect a mix of cash bonuses for commercial targets and equity-based awards (RSUs/options and milestone‑ or performance‑based vesting) common in Biotechnology, with supplemental retention packages to support rapid field expansion. Because R&D spend and regulatory outcomes materially affect capital needs, some incentive design may also reward successful partnering / out‑license milestones.

Insider Trading Considerations

Watch insider transaction timing around high‑signal events: quarterly results, clinical readouts (Ersa/Rhea/Galatea/Carpo), regulatory milestones in Japan and the EU, and material reimbursement or payer developments—these are windows when insiders may be more likely to trade or to be subject to blackout periods. The March 2025 follow‑on offering likely included lock‑up and resale constraints that could have limited insider sales in the months after, and many executives will use 10b5‑1 plans to avoid appearance issues when selling; all Section 16 insiders must also file Form 4 promptly. Given the company’s remaining capital cadence and potential need to raise funds, insider sales (or lack thereof) may be interpreted by traders as signals about management’s view of valuation and funding prospects, so monitor filings and any newly adopted trading plans closely.